Pneumologie (Stuttgart, Germany)最新文献

{"title":"[Is the tobacco industry reinventing itself?]","authors":"Wulf Pankow, Karin Vitzthum, Natascha Sommer, Reiner Hanewinkel, Stefan Andreas","doi":"10.1055/a-2847-7259","DOIUrl":"10.1055/a-2847-7259","url":null,"abstract":"<p><strong>Abstract: </strong>The tobacco industry has repeatedly adjusted its product strategy in the past. As soon as the health risks of tobacco use could no longer be denied, it responded with high-profile campaigns designed to downplay scientific findings. In addition, it introduced modified products such as cigarette filters and so-called \"light\" cigarettes, which give the impression of being less harmful. This strategy has become increasingly less successful in recent years. Public health policies focused on environmental prevention, combined with increased public awareness, have led to a global decline in tobacco consumption. With new nicotine products such as e-cigarettes, tobacco heaters, and nicotine pouches, an additional market segment is now being developed to complement the shrinking core market. And once again, the health risks associated with the mechanism of addiction are downplayed as \"harm reduction\". New products are redefined as therapeutic aids for smoking cessation, through which the tobacco industry seeks to present itself as a pharmaceutical entity. At the same time, the company will continue to operate in the core market for tobacco products as part of a two-pronged strategy, and this product segment is expected to remain the dominant source of revenue and profit for the foreseeable future. In this respect, the tobacco industry is adapting to the new circumstances without abandoning the business model based on nicotine addiction.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":"712-718"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148820960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[80 Years of \"Pneumologie\" - Occupational Medicine and Occupational Diseases: Then and Now].","authors":"Marcial Velasco Garrido","doi":"10.1055/a-2842-3240","DOIUrl":"10.1055/a-2842-3240","url":null,"abstract":"<p><strong>Abstract: </strong>The journal \"Der Tuberkulosearzt\" was first published in October 1947; following two name changes - to \"Praxis der Pneumologie\" in 1964 and \"Praxis und Klinik der Pneumologie\" in 1977 - it has been known to its readership as \"Pneumologie\" since 1989. After briefly reviewing the historical context at the time of the journal's inaugural issue, this paper presents a bibliometric analysis of articles related to occupational medicine published over the 80-year history of the journal now known as \"Pneumologie\". Subsequently, the first three articles dedicated to occupational medicine topics are presented as case studies, and the relevance of their content is discussed from a modern perspective.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":"719-730"},"PeriodicalIF":1.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148805315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Use of Disposable E-Cigarettes and Concurrent Use of Other Nicotine Products in Adolescence: A Cross-Sectional Analysis of 28,554 Students (Prevention Radar 2025/2026)].","authors":"Julia Hansen, Clemens Neumann, Reiner Hanewinkel","doi":"10.1055/a-2958-1312","DOIUrl":"https://doi.org/10.1055/a-2958-1312","url":null,"abstract":"<p><strong>Background: </strong>This study, conducted as part of the Prevention Radar 2025/2026, aimed to describe the 30-day prevalence of disposable e-cigarette use compared to other nicotine products among German adolescents and to analyze patterns of concurrent use.</p><p><strong>Methods: </strong>Cross-sectional data from n=28,554 students across 15 federal states were analyzed (collection period 2025/2026; mean age: 13.3 years, SD=1.75; 51.5% female, 1.2% diverse; 62.4% academic-track secondary school). The sample comprised early (11-14 years; 71.7%) and late adolescence (15-17 years; 28.3%). 30-day prevalence was assessed for disposable e-cigarettes, reusable e-cigarettes, tobacco cigarettes, and waterpipes. For current disposable e-cigarette users (n=2,255), product combinations were determined.</p><p><strong>Results: </strong>Disposable e-cigarettes exhibited numerically the highest 30-day prevalence at 8.9%, followed by conventional cigarettes (7.5%), reusable e-cigarettes (7.4%), and waterpipes (2.6%). Given the overlapping confidence intervals, the prevalence rates of disposable e-cigarettes, conventional cigarettes, and reusable e-cigarettes remain at a comparable level. Prevalence rates were significantly higher in late adolescence than in early adolescence (disposable e-cigarettes: 19.4% vs. 4.9%). Gender differences were minimal (girls: 9.0%; boys: 8.5%), while use of all products examined was roughly twice as high among students at other school types compared to those attending Gymnasium (disposable e-cigarettes: 11.8% vs. 5.3%). Within the subgroup of disposable e-cigarette users (n = 2,255), only 15.9% reported exclusive use. The majority additionally used reusable e-cigarettes (70.6%) and/or conventional cigarettes (61.3%). Overall, 34.5% reported consuming two additional products, and 18.4% reported using all three accompanying product categories concurrently.</p><p><strong>Conclusion: </strong>Disposable e-cigarettes represent numerically the most frequently used nicotine product in the sample, yet remain epidemiologically on par with conventional cigarettes and reusable e-cigarettes. Isolated mono-use represents the exception; the vast majority of users exhibit concurrent use of multiple products. Prevention approaches should address this pronounced simultaneous use of multiple nicotine products and not narrow their focus to single product categories.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Documentation of biological treatment in asthma].","authors":"Marek Lommatzsch, Roland Buhl, Randolf Brehler, Eckard Hamelmann, Marcus Joest, Kristin Aufm Kampe, Stephanie Korn, Sabine Lampert, Norbert Mülleneisen, Christian Taube, Jordis Trischler, Christian Vogelberg, Florian Schmitz, Ludger Klimek","doi":"10.1055/a-2842-7870","DOIUrl":"10.1055/a-2842-7870","url":null,"abstract":"<p><strong>Background: </strong>Biologics are the first-line treatment for patients with severe, poorly controlled asthma and can lead to a significant reduction (or even complete avoidance) of exacerbations and the need for systemic corticosteroids - which are associated with numerous side effects - as well as to a marked improvement in asthma control and lung function in severe asthma. Due to the high annual costs of biologic therapy, there is a legitimate interest on the part of payers in the cost-effective use of biologics for severe asthma in accordance with guidelines and regulatory approvals; conversely, there is a legitimate interest on the part of treating physicians in prescribing these biologics in a manner that protects them from liability claims.</p><p><strong>Methodology: </strong>In an analysis of the literature and regulatory approvals, combined with the experience of the participating authors, evidence was compiled regarding therapy with the biologics approved for severe asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and depemokimab.</p><p><strong>Results: </strong>Based on guideline recommendations and approvals, recommendations are provided for the use of the aforementioned biologics within the German healthcare system. In a joint effort by various professional societies (AeDA, DGP, BdP, GAN, DGAKI, GPP, GPA), documentation forms were created for all biologics approved for severe asthma, which can serve as a basis for documentation. Forms were developed both for initiating biologic therapy and for documenting the course of biologic therapy in severe asthma.</p><p><strong>Conclusion: </strong>The new documentation forms provide a practical, one-page summary of all key points regarding the prescription of biologics and the assessment of response to biologics in severe asthma, serving both to ensure prescribing in accordance with guidelines and regulatory requirements and to prevent drug-related claims.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":"631-640"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[In reply].","authors":"Christian Taube, Wolfram Windisch, Martin Witzenrath","doi":"10.1055/a-2921-8736","DOIUrl":"https://doi.org/10.1055/a-2921-8736","url":null,"abstract":"","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":"80 9","pages":"626"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Follow-up after lung transplantation: a complex and interdisciplinary task].","authors":"Annika Geist, Björn Kleibrink, Achim Koch, Christian Taube","doi":"10.1055/a-2756-7690","DOIUrl":"10.1055/a-2756-7690","url":null,"abstract":"<p><strong>Abstract: </strong>Follow-up of lung transplant patients is complex and requires highly specialized and interdisciplinary collaboration both in inpatient and outpatient settings. A structured approach became available in Germany, Austria and Switzerland when the first guideline for the follow-up care of lung transplant recipients was published in 2025.Regular follow-up intends to prevent or detect allograft dysfunction at an early stage. Bronchopulmonary infections, acute or chronic rejection and airway complications are the main causes of allograft dysfunction. This has to be considered in diagnostic pathways.Furthermore, it is essential to closely monitor possible toxicities and long-term side effects of immunosuppressive medication. These toxicities include renal insufficiency, diabetes mellitus, osteoporosis, arteriosclerosis, chronic infection and the development of malignant neoplasm.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":"80 9","pages":"664-674"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Differences between women and men in rheumatic systemic diseases with lung involvement].","authors":"Melanie Berger, Doreen Kroppen, Maximilian Zimmermann, Franziska Vocht, Daniel Sebastian Majorski, Niklas Ploenes, Ramona Gilles, Maximilian Wollsching-Strobel, Johannes Strunk, Wolfram Windisch, Falk Schumacher","doi":"10.1055/a-2852-5603","DOIUrl":"10.1055/a-2852-5603","url":null,"abstract":"<p><strong>Background: </strong>Biological sex has a significant impact on the prevalence and course of lung involvement and inflammatory rheumatic diseases (IRD). However, data and analyses addressing this relationship are lacking for Germany.</p><p><strong>Methods: </strong>In a retrospective analysis, data from the German Federal Statistical Office were evaluated using hospital discharge diagnoses coded according to the International Classification of Diseases (ICD-10) from 2005 to 2023. Frequency, temporal trends, and distribution were analysed separately for women and men. Eleven rheumatologic diseases as primary diagnoses were included: rheumatoid arthritis (M05, M06), connective tissue diseases (M32-M35), and ANCA-associated vasculitis (M30.1, M31.3, M31.7). Each was combined with five secondary diagnoses indicating pulmonary involvement (J84.1, J84.8, J84.9, J99.0*, J99.1*).</p><p><strong>Results: </strong>Over the 19-year observation period, the total number of hospitalizations for women with IRD (n = 734,167; 68%) exceeded that of men (n = 349,806; 32%). The absolute number of cases with lung involvement associated with IRD was also higher in women (n = 88,936) than in men (n = 52,523). However, the relative proportion of lung involvement among patients with IRD was higher in men compared to women (15% vs. 12%). In both sexes, case numbers increased steadily over the study period, with a transient decline in 2020. The rise in cases with lung involvement among patients with IRD over time was more pronounced in men.</p><p><strong>Discussion: </strong>The number of hospitalized patients with lung involvement secondary to IRD has increased continuously over the past 19 years. Male patients with IRD appear to have a higher risk of developing lung involvement compared to female patients.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":"648-654"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Re: Innovation much later - or not at all? The impact of the Most-Favored-Nation price in the United States on pulmonary medicine in Germany].","authors":"Dieter Köhler","doi":"10.1055/a-2917-4696","DOIUrl":"https://doi.org/10.1055/a-2917-4696","url":null,"abstract":"","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":"80 9","pages":"623-625"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kommentar.","authors":"Niels Reinmuth","doi":"10.1055/a-2767-8884","DOIUrl":"https://doi.org/10.1055/a-2767-8884","url":null,"abstract":"","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":"80 9","pages":"663"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Myositis and NSCLC: an interdisciplinary case report].","authors":"Marie-Kristin Bärmann, Mark Uhlenbruch, Aris Koryllos, Stefan Krüger, Hartwig Schütte","doi":"10.1055/a-2867-9847","DOIUrl":"10.1055/a-2867-9847","url":null,"abstract":"<p><strong>Abstract: </strong>Rheumatological diseases such as myositis might be detected during the diagnostic process of lung cancer.This suggests the need for interdisciplinary dialogue concerning thoracooncological and immunosuppressive treatment of myositis and associated interstitital lung diseases. In particular, the side effects of checkpoint inhibitors must be taken into consideration.This case report is about the detection of myositis-associated interstitial lung disease in the course of a thoracooncological treatment regimen.</p>","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":"80 9","pages":"660-662"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149019537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}